NET LOSS PER SHARE (Details Narrative) - shares |
12 Months Ended | ||
---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2023 |
|
Outstanding stock options | 343,667,000 | 540,881,000 | 270,000,000 |
Restricted stock outstanding | 193,857 | ||
Warrants outstanding | 82,500 | ||
Antidilutive securities excluded from computation of earnings per share, amount, shares | 82,500 | ||
Common Stock [Member] | |||
Outstanding stock options | 343,667 | ||
Warrant [Member] | |||
Outstanding stock options | 540,881 | ||
Restricted stock outstanding | 681,315 |
X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|